• Skip to main content
  • Skip to footer
Minority News Logo

Black Radio Network

The world you see depends upon the news you get. ®

Home › RSS › DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

October 9, 2024 by |

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has issued approval to proceed with the planned two-part Phase 2 s

Filed Under: RSS

Footer

To Reach Us


Email:
news@blackradionetwork.com
news@minoritynews.net
news@minoritynewsservice.com

Address:
Black Radio Network
375 Fifth Avenue
New York, NY 10016

Phone Numbers:
Ph # (212) 686-6850
Fx # (212) 686-7308


Copyright © 2025 · Black Radio Network, Inc. All rights reserved. · About · Privacy · Terms of Use